We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, raising a whopping $604 million, although its shares retreated 19% after the debut......
Moderna Therapeutics, which is pushing a pipeline of mRNA candidates into phase 2 trials, now has a manufacturing plant ready to advance its highly anticipated program.
On the heels of a massive $500 million round, Moderna has picked up another $125 million in preferred equity as it expands its mRNA cancer vaccine partnership with Merck.